In agreement with these findings, our results showed that, due to the presence of a negative interaction between ERLBA and VEGF, already observed in a series of N− cancers (Coradini et al, 2001), patients whose tumours had a low/intermediate ERLBA content exhibited an increased risk of disease recurrence with increasing values of intratumoral VEGF. The gene discussed is VEGFA; the disease is cancer.